10-Q: MariMed Inc. Reports First Quarter 2024 Results, Revenue Up 10.3%

MariMed Inc. saw a 10.3% increase in revenue in the first quarter of 2024 compared to the same period last year, driven by wholesale growth, while also reporting a net loss.

Summary

• MariMed Inc. reported a revenue of $37.9 million for the first quarter of 2024, a 10.3% increase compared to $34.4 million in the same period of 2023.
• The company's product revenue increased by 9.8%, with wholesale revenue growing by 39.8% while retail revenue decreased by 3.6%.
• The company experienced a net loss of $1.3 million, compared to a net loss of $0.7 million in the first quarter of 2023.
• Operating expenses increased by 40.9% to $14.5 million, primarily due to higher personnel, marketing, and general and administrative costs.
• The company's gross profit was $16.5 million, with a gross margin of 43.4%, slightly down from 44.8% in the prior year period.
• Adjusted EBITDA was $4.7 million, compared to $7.1 million in the first quarter of 2023.

Sentiment

Score: 5

Explanation: The document presents mixed results with revenue growth offset by increased expenses and a net loss. The acquisitions are positive, but the overall financial performance is concerning.

Positives

• The company experienced a significant increase in wholesale revenue, indicating strong growth in that segment.
• Total revenue increased by 10.3% year-over-year.
• The company completed two acquisitions in April 2024, expanding its footprint.

Negatives

• The company reported a net loss of $1.3 million for the quarter.
• Retail product revenue decreased by 3.6%.
• Operating expenses increased significantly by 40.9%, impacting profitability.
• Gross margin decreased slightly from 44.8% to 43.4%.

Risks

• The company's operating expenses are increasing, which could impact future profitability.
• The company is subject to ongoing business risks that affect the estimation process of the carrying value of assets and the recording of liabilities.
• The company's income tax provisions are impacted by Section 280E of the Internal Revenue Code, which prohibits the deduction of certain ordinary business expenses.
• The company is subject to legal claims from time to time.

Future Outlook

The company is focused on executing its strategic growth plan, including completing acquisitions, increasing revenue organically, expanding its footprint, and increasing product brand revenue. The company believes its current cash and future funding opportunities will be sufficient to meet its anticipated cash needs for at least the next twelve months.

Management Comments

• Management believes that Adjusted EBITDA is a useful measure to assess the company's performance and liquidity.
• Management uses Adjusted EBITDA to understand and compare operating results across accounting periods, and for financial and operational decision-making.

Industry Context

The cannabis industry is experiencing growth, and MariMed is positioning itself to capitalize on this trend through strategic acquisitions and expansion. The company's focus on both retail and wholesale channels, as well as its branded products, aligns with industry trends.

Comparison to Industry Standards

• While MariMed's revenue growth of 10.3% is positive, it is important to compare this to other multi-state operators (MSOs) in the cannabis industry. Companies like Curaleaf, Green Thumb Industries, and Trulieve have reported varying growth rates, and a detailed comparison would be needed to assess MariMed's performance relative to its peers.
• The company's gross margin of 43.4% is within the range of other MSOs, but it is important to analyze the specific factors affecting this margin, such as pricing, cost of goods sold, and operational efficiency.
• The company's adjusted EBITDA of $4.7 million is a key metric for assessing profitability, but it is important to compare this to the EBITDA margins of other MSOs to determine if MariMed is performing at or above industry standards.
• The company's recent acquisitions of MedLeaf and Allgreens are in line with the industry trend of consolidation and expansion, but the success of these acquisitions will depend on the company's ability to integrate them effectively and generate synergies.

Related Party Transactions

• The company leases its corporate offices from an entity in which the CEO has an investment interest.
• The company procures nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the family of the COO.
• The company pays royalties on the revenue generated from its Bettys Eddies product line to an entity owned by the COO and the CRO.
• One of the company's majority-owned subsidiaries paid distributions to the CEO, who owns a minority equity interest in such subsidiary.
• The company's mortgages with Bank of New England and DuQuoin State Bank were personally guaranteed by the CEO.

Stakeholder Impact

• Shareholders may be concerned about the net loss and increased operating expenses.
• Employees may be impacted by the company's growth and expansion plans.
• Customers may benefit from the company's expanded product offerings and retail locations.
• Suppliers may see increased business opportunities as the company grows.
• Creditors may be impacted by the company's debt obligations and financial performance.

Next Steps

• The company plans to reopen the MedLeaf dispensary and begin adult-use retail sales by the end of the second quarter of 2024.
• The company will continue to focus on executing its strategic growth plan, including completing acquisitions, increasing revenue organically, expanding its footprint, and increasing product brand revenue.

Key Dates

Keywords

cannabis, marijuana, multi-state operator, dispensary, cultivation, wholesale, retail, revenue, EBITDA, acquisition, licenses